Advertisement
Advertisement
December 17, 2012
Cook Launches Zilver PTX Peripheral Drug-Eluting Stent in the United States
December 18, 2012—Cook Medical (Bloomington, IN) announced the first commercial use of the Zilver PTX paclitaxel-eluting stent in the United States. The device received US Food and Drug Administration approval on November 15. The commercial launch commenced with the first procedure being conducted by Gary Ansel, MD, at the Riverside Methodist Hospital in Columbus, Ohio. Dr. Ansel served as a Principal Investigator in the global Zilver PTX trial.
Zilver PTX is approved for use in the above-the-knee femoropopliteal artery for the treatment of peripheral artery disease (PAD). The device is currently available in 54 markets, including the European Union, Brazil, Australia, Taiwan, and Japan.
“It was a great honor for my institution to be first to implant Cook Medical’s Zilver PTX as part of the stent’s commercial roll-out,” commented Dr. Ansel, Director for the Center for Critical Limb Care at Riverside Methodist Hospital, in the company’s press release. “This technology is so advanced and offers such prolonged patient benefit, I believe it will very quickly challenge older PAD treatments such as balloon angioplasty and bare-metal stenting in the US as the standard of PAD care.”
Advertisement
Advertisement
